8963:TSEInvincible Investment Corp. Analysis
Data as of 2026-06-19 - not real-time
Latest Price
Risk Level: Medium
Executive Summary
Invincible Investment Corp (8963.T) is trading at ¥60,700, just below its 20‑day SMA of ¥60,865 and well under the 50‑day SMA of ¥61,430, signaling a short‑term bearish bias. The RSI sits at 47.9, indicating neutral momentum, while the MACD histogram is positive (+¥83.2) and the MACD signal is flagged bullish, suggesting a potential near‑term bounce. Valuation appears attractive on a price‑earnings basis at 14.96×, far below the industry average of 32.31×, yet the discounted cash‑flow model estimates a fair value of only ¥19,880, implying the market price may be significantly overvalued. The REIT carries a heavy debt load (Debt‑to‑Equity 105%) with cash reserves covering only ~8% of total debt, and it currently distributes no dividend, raising concerns about cash flow sustainability. On the risk side, beta is low at 0.34, indicating limited market volatility, but volume is decreasing and 30‑day volatility is moderate at 15.8%, adding liquidity pressure. Overall, the blend of a strong hotel asset base, low market sensitivity, and attractive PE is offset by high leverage, zero dividend yield, and a price that exceeds DCF expectations.
Market Outlook
Short Term
< 1 yearKey Factors
- Price below short‑term moving averages and near support
- Decreasing trading volume indicating waning liquidity
- High leverage with debt‑to‑equity exceeding 100%
Medium Term
1–3 yearsKey Factors
- PE ratio well below industry average suggesting valuation upside
- Low beta and moderate volatility offering defensive characteristics
- Potential recovery in hotel occupancy supporting earnings
Long Term
> 3 yearsKey Factors
- Largest hotel portfolio among Japanese REITs providing asset quality
- Absence of dividend payouts limiting total return potential
- Sustained high debt levels that could constrain future growth
Key Metrics & Analysis
REIT Metrics
Technical Analysis
Risk Assessment
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.